Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.40 |
| ▸ | USP2 | O75604 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14874683 | 0.83 | CYP1A2 (0.40) | CYP1A2USP2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL14741947 | 0.82 | KMO (0.44) | NPSR1MAP4K4EGFRFRKMAPK9 | |
| SCHEMBL14874681 | 0.79 | KMT2A (0.56) | NPSR1KMT2ACYP1A2USP2CYP3A4 | |
| SCHEMBL28280894 | 0.78 | NPSR1 (0.56) | NPSR1KMT2ACYP1A2USP2TSHR | |
| SCHEMBL4049174 | 0.75 | TRPV1 (0.47) | NOTUMMAPK1ALDH1A1KDM4E | |
| SCHEMBL4624996 | 0.75 | NOTUM (0.49) | NOTUMKMT2ACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL3296527 | 0.73 | DPP4 (0.46) | KMT2ACYP1A2USP2TSHRCYP3A4 | |
| SCHEMBL3311451 | 0.73 | CYP1A2 (0.43) | NPSR1KMT2ACYP1A2USP2TSHR | |
| SCHEMBL10628766 | 0.71 | NOTUM (0.45) | NOTUMCYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL3820660 | 0.71 | RPS6KA3 (0.44) | NOTUMALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741316-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6872717-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ACHARD DANIEL (FR) | 2003-03-20 | — | — | US | disclosed |
| US-6479479-B2 | 1-DIARYLMETHYL-4-ALKYL OR ALKYLSULFONYLALKYL-AZETIDINES; CANNABINOID RECEPTOR ANTAGONISTS; NERVOUS SYSTEM DISORDERS (CNS); CARDIOVASCULAR AND GLANDULAR DISORDERS; DRUG ABUSE; PSYCHOLOGICAL DISORDERS; | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | NPSR1 1896/4885NOTUM 3330/4885KMT2A 2635/4885 |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | NPSR1 1896/4885NOTUM 3330/4885KMT2A 2635/4885 |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | CHRM2, ACHE, DRD2 | NPSR1 270/4885NOTUM 1412/4885KMT2A 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.